Related Experiment Video
Updated: Jan 16, 2026
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
646
Breast Cancer Polygenic Risk Score Associated with Outcomes after In Situ Breast Disease
Jasmine Timbres1, Kelly Kohut2, Nasim Mavaddat3
1Breast Cancer Genetics, King's College London, London, United Kingdom.
Summary
A polygenic risk score (PRS313) can predict future breast cancer risk in women diagnosed with ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). This score helps identify high-risk individuals for personalized breast cancer management.
Area of Science:
- Oncology
- Genetics
- Breast Cancer Research
Background:
- Ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS) are preinvasive breast lesions with varying risks of progression.
- Both DCIS and LCIS increase the risk of developing contralateral breast cancer, necessitating risk stratification.
- Identifying high-risk patients is crucial for personalizing treatment and surveillance strategies for in situ breast cancers.
Purpose of the Study:
- To evaluate the predictive capability of the 313-SNP polygenic risk score (PRS313) for subsequent breast cancer events.
- To assess PRS313's accuracy in predicting ipsilateral and contralateral breast cancer development after DCIS or LCIS diagnosis.
Main Methods:
- Analysis of data from the ICICLE and GLACIER studies, including 2,169 DCIS and 185 LCIS patients.
- Utilizing a 313-SNP polygenic risk score (PRS313) to assess genetic predisposition to breast cancer.
- Employing Cox regression analysis with a median follow-up of 11 years to evaluate outcomes.
Main Results:
- A significant association was found between PRS313 and contralateral breast disease risk following DCIS (HR=1.30).
- PRS313 was linked to an increased risk of ipsilateral breast disease after LCIS diagnosis (HR=2.16).
- The study demonstrates PRS313's potential in predicting diverse breast cancer events post-in situ diagnosis.
Conclusions:
- PRS313 is a valuable predictor of future breast cancer events in women with in situ breast cancer.
- The score shows specific utility in predicting contralateral disease after DCIS and ipsilateral disease after LCIS.
- PRS313 can inform clinical decisions regarding surveillance and risk-reduction strategies for improved patient outcomes.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
407
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
407
01:21Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648